Weinberg Capital Partners, the French mid-market buyout firm started by PPR’s former chairman Serge Weinberg, has agreed its first deal by acquiring 70% of Pharma Omnium International on an expected enterprise value of about €100m (US$127.6m).
The deal with Pharma Omnium’s founders, Frédéric Champavere and Philippe Pasdelou, provides the company with enough undisclosed capital to buy French pharmaceuticals company, Laboratoires Biodim, and more than doubles its revenues.
Biodim owns the Témesta, Séresta, Uteplex, Colprone and Lederthrexate products and had sales of €43.7m last year.
Champavere was a former president of Janssen-Cilag and Lilly while Pasdelou was a former president of Madaus and set up Pharma Omnium to consolidate the sector. Its last deal was buying JCD in January.